Impact of Cyp2c19 Allele 17 Mutase on Clopidogrel Hyper-Responsiveness in Indonesian Patients with Ischemic Stroke

BACKGROUND: Ischemic stroke dominated up to 76% of the 101.5 million stroke cases globally. One of the treatments for stroke is secondary prevention by administering antiplatelet. Clopidogrel is an add-on antiplatelet to the dual antiplatelet therapy (DAPT) regimen. In its metabolism, clopidogrel can show the nature of resistance and bleeding risk. Studies on resistance have been widely put forward but not with the bleeding. The study of the bleeding risk to Asian races focused only on East Asian races. AIM: The objective of the study is to determine the bleeding risk in the Indonesian population and the correlation with the polymorphism of CYP2C19 allele 17. METHODS: There were 112 participants in this study. About 45.5% showed a normal response to clopidogrel, but 40.2% had a bleeding risk. All participants (100.0%) had mutations in CYP2C19 allele 17, with 47.3% being intermediate metabolizers. RESULTS: The bleeding risk was significantly correlated with clopidogrel (p: 0.02). The Indonesian population has a high bleeding risk from the clopidogrel administration. CONCLUSION: Compared to DAPT administration, clopidogrel can be a monotherapy for secondary stroke prevention.

[1]  Sathish Kumar Jayapal,et al.  Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2021, The Lancet. Neurology.

[2]  H. Yasunaga,et al.  Association of Body Mass Index with Ischemic and Hemorrhagic Stroke , 2021, Nutrients.

[3]  H. Kamel,et al.  2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. , 2021, Stroke.

[4]  K. Bailey,et al.  Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. , 2021, JACC. Cardiovascular interventions.

[5]  Hao Li,et al.  Severity of Nonalcoholic Fatty Liver Disease and Risk of Future Ischemic Stroke Events , 2020, Stroke.

[6]  Elizabeth C. Whipple,et al.  Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta‐Analysis , 2020, Clinical and translational science.

[7]  K. Filipska,et al.  The Phenomenon of Clopidogrel High On-Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive Review , 2020, International journal of molecular sciences.

[8]  R. Sartika,et al.  Body mass index of adults, pre-elderly and elderly in Indonesia (Indonesian Family Life Survey 2014) , 2020 .

[9]  Jeehoon Kang,et al.  Ethnic Differences in Oral Antithrombotic Therapy , 2020, Korean circulation journal.

[10]  J. Stine,et al.  Nonalcoholic fatty liver disease- evidence for a thrombophilic state? , 2020, Current pharmaceutical design.

[11]  Sidney C. Smith,et al.  2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. , 2019, Science bulletin.

[12]  Deepak L. Bhatt,et al.  Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs , 2018, Thrombosis and Haemostasis.

[13]  H. Chen,et al.  Patients with Cerebral Stroke Have an Increased Risk of Gastroesophageal Reflux Disease: A Population-Based Cohort Study. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[14]  G. Lemesle,et al.  Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5‐Year CORONOR Registry , 2018, Journal of the American Heart Association.

[15]  M. Alfonso,et al.  Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism , 2018, Journal of Thrombosis and Thrombolysis.

[16]  C. Held,et al.  Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial , 2018, Journal of the American Heart Association.

[17]  Joshua C Denny,et al.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. , 2018, JACC. Cardiovascular interventions.

[18]  F. Silver,et al.  Acute ischemic stroke and abnormal blood hemoglobin concentration , 2016, Acta neurologica Scandinavica.

[19]  S. Judd,et al.  Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults , 2016, Stroke.

[20]  Braxton D Mitchell,et al.  Obesity Increases Risk of Ischemic Stroke in Young Adults , 2015, Stroke.

[21]  J. Spertus,et al.  Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel-Treated Patients After Acute Myocardial Infarction , 2014, Circulation. Cardiovascular genetics.

[22]  R. Conwit,et al.  Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design , 2013, International journal of stroke : official journal of the International Stroke Society.

[23]  Liping Liu,et al.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.

[24]  A. Shuldiner,et al.  The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. , 2011, American heart journal.

[25]  I. Lozano,et al.  Letter by Lozano et al regarding article, "Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent)". , 2010, Circulation. Cardiovascular interventions.

[26]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.

[27]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[28]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .